Axonics Acquires Contura and Its Urethral Bulking Agent for $200 Million
Irvine, Calif-based Axonics Modulation Technologies has purchased Contura for $200 million, a move that earns it the company’s flagship product Bulkamid, a urethral bulking agent.
Bulkamid is a hydrogel injected into the urethral wall in a minimally invasive office or outpatient procedure to restore the urethra’s natural closing pressure. It is used as a treatment for stress urinary incontinence (SUI).
SUI is a condition often associated with childbirth and is prevalent among women of all ages, including an estimated 20 million in the U.S. alone.